leifsmith
I have long been aware of the huge pharma forces who want to see MyMD Pharma fail. It is because of this, that as we approach phase 2 human trials, I would like to see MyMD adopt a licensing and royalty approach, whereby any successful phase 2 human study would be licensed to an appropriate international pharmaceutical company for the required phase 3 human study. This would pass on the huge expense of phase 3 studies to companies that can afford it, while making them partners in this new field of medical science.
News 
Market Data 
Discover 
